作者
Marina Chiara Garassino, Alain Jonathan Gelibter, Francesco Grossi, Rita Chiari, Hector Soto Parra, Stefano Cascinu, Francesco Cognetti, Daniele Turci, Livio Blasi, Carmelo Bengala, Enrico Mini, Editta Baldini, Silvia Quadrini, Giovanni Luca Ceresoli, Paola Antonelli, Enrico Vasile, Carmine Pinto, Gianpiero Fasola, Domenico Galetta, Marianna Macerelli, Diana Giannarelli, Giuseppe Lo Russo, Filippo de Marinis
发表日期
2018/8/1
期刊
Journal of Thoracic Oncology
卷号
13
期号
8
页码范围
1146-1155
出版商
Elsevier
简介
Introduction
Nivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous NSCLC. We report results from the nivolumab Italian expanded access program focusing on never-smokers and patients with EGFR-mutant nonsqamous NSCLC.
Methods
Nivolumab (3 mg/kg intravenously every 2 weeks) was administered upon physicians’ request to patients who had relapsed after one or more prior systemic treatments for stage IIIB/IV nonsquamous NSCLC. Efficacy and safety were evaluated in patients who received at least one dose of nivolumab.
Results
Of 1588 patients with nonsquamous NSCLC, 305 (19.2%) were never-smokers. EGFR status was available for 1395 patients. Of the 102 patients (6.4%) with EGFR mutation–positive tumors, 51 (50%) were never-smokers. The objective response rate was significantly higher in patients with wild-type EGFR than patients with EGFR-mutant tumors …
学术搜索中的文章
MC Garassino, AJ Gelibter, F Grossi, R Chiari… - Journal of Thoracic Oncology, 2018